590.00
+0.85%
Close of 9 Nov 2026, in DKK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Strategic Partners A/S
Its shares trade on Nasdaq Copenhagen under the ticker STRAP.CO. It has been listed since 17 November 2017. In the fiscal year to 31 December 2024, it reported a net loss of DKK 298,000. At that date it held total assets of DKK 23.6m and shareholders' equity of DKK 19.2m.
Orphazyme A/S engages in development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Nov 2017
- Employees
- 141
- Website
- orphazyme.com ↗
Leadership
Pay as last reported
- Dr. Georges GemayelIndependent Chairman of the BoardDKK 2.2m
- Dr. Bo Jesper HansenIndependent Deputy Chairman of the BoardDKK 612,000
- Mr. Lars AndersenDirector
- Mr. Andrew MerciecaIndependent DirectorDKK 24,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Orphazyme A/S focuses on rare disease treatments with arimoclomol for lysosomal storage diseases.
- The company collaborates with academic institutions in Europe and the United States for research.
- Orphazyme A/S has 141 employees dedicated to biotechnology development.
Weaknesses
- Orphazyme A/S is listed on the Copenhagen Stock Exchange since 2017.
- The company operates in a niche biotechnology sector with limited market size.
- Orphazyme A/S has no commercialized products yet in the rare disease market.
Opportunities
- Orphazyme A/S can expand into new rare disease segments beyond lysosomal storage diseases.
- The company may benefit from increased global focus on rare disease treatments.
- Collaborations with academic institutions could lead to new therapeutic discoveries.
Threats
- Orphazyme A/S faces competition from other biotechnology firms in rare disease research.
- Regulatory challenges may delay the approval of arimoclomol for clinical use.
- The high cost of developing new therapies for rare diseases poses financial risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.